India, April 3 -- This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts across therapeutic areas like Psoriasis, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Atopic Dermatitis, IgA nephropathy, Non-small cell lung cancer, and Thyroid eye disease.

Let's dive into the details.

FDA and EU Approvals & Rejections

ARS Pharma Gains FDA Approval to Broaden Neffy Label for Allergic Reactions

ARS Pharmaceuticals (SPRY) received FDA approval to update the label for Neffy 1mg, its needle-free epinephrine nasal spray, removing the prior age restriction. It can now be used by anyone weighing 33 lbs or more - both child...